OncoMatch/Clinical Trials/NCT04835584
KRT-232 and TKI Study in Chronic Myeloid Leukemia
Is NCT04835584 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including KRT-232 and Dasatinib for chronic myeloid leukemia.
Treatment: KRT-232 · Dasatinib · Nilotinib — This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Ph+ Chronic Myeloid Leukemia (CML) who have relapsed or are refractory or intolerant to a Tyrosine Kinase Inhibitor (TKI). This study is a global, open label Phase 1b/2 to determine the efficacy and safety of KRT-232 in patients with chronic phase CML (CML-CP) and accelerated phase (CML-AP) who have failed TKI treatments.
Check if I qualifyExtracted eligibility criteria
Cancer type
Chronic Myeloid Leukemia
Biomarker criteria
Required: TP53 wild-type
Documented TP53wt
Required: BCR ABL1 fusion
BCR-ABL+
Required: ABL1 BCR fusion
BCR-ABL+
Excluded: ABL1 T315I
Known T315I mutation
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: bcr-abl inhibitor
Cannot have received: mdm2 antagonist
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama Birmingham · Birmingham, Alabama
- Georgia Cancer Center at Augusta University · Augusta, Georgia
- University of Pittsburgh Medical Center · Pittsburgh, Pennsylvania
- Texas Oncology- Sammons CC at Baylor · Dallas, Texas
- Medical College of Wisconsin · Milwaukee, Wisconsin
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify